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Aim: To assess both serum concentration of metallotionein (MT) and anti-metallothionein 
(anti-MT) immunoglobulin G (IgG) in autistic children with gastrointestinal (GI) symptoms 
and controls, and to test the hypothesis that there is an association between the presence of 
MT, anti-MT IgG, and inﬂ  ammatory GI disease seen in many children with autistic spectrum 
disorder (ASD).
Subjects and methods: ELISAs were used to measure serum MT and anti-MT IgG in 
41 autistic children with chronic digestive disease (many with ileo-colonic lymphoid nodular 
hyperplasia [LNH] and inﬂ  ammation of the colorectum, small bowel, and/or stomach), and 
33 controls (17 age-matched autistic children with no GI disease and 16 age-matched children 
without autism or GI disease).
Results: Ten of 41 autistic children with chronic digestive disease had high serum concentration 
of MT compared to only one of the 33 controls (p  0.01). Thirteen of the 41 autistic children 
with chronic digestive disease had anti-MT IgG compared to only four of 33 controls (p  0.01). 
Nine of 10 (90%) of autistic children with GI disease with high MT levels had a regressive 
onset (compared to the expected 25 of 41, or 61%, in this group) (p  0.05), whereas only nine 
of 13 of the autistic children with GI disease and anti-MT IgG had a regressive onset (70%) 
which was not signiﬁ  cantly higher than the expected. We didn’t ﬁ  nd any correlation between 
severity of GI disease and MT concentration or anti-MT IgG.
Discussion: These results suggest a relationship between MT, anti-MT IgG and GI disease 
seen in many ASD individuals.
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Introduction
Autistic spectrum disorder (ASD) is a neurodevelopmental syndrome with onset prior 
to age 36 months. Diagnostic criteria consist of impairments in sociality and com-
munication plus repetitive and stereotypic behaviors.1 Traits strongly associated with 
autism include movement disorders and sensory dysfunctions.2 Although autism may 
be apparent soon after birth, most autistic children experience at least several months, 
up to a year or more in some cases, of normal development, followed by regression, 
deﬁ  ned as loss of function or failure to progress.2–4
The neurotoxicity of mercury (Hg) has long been recognized.5 Primary data come 
from victims of contaminated ﬁ  sh or grain, from acrodynia induced by Hg in teething 
powders, and from individual instances of mercury poisoning (HgP), many occurring 
in occupational settings. More recently, the Food and Drug Administration (FDA) 
and the American Academy of Pediatrics (AAP) have determined that the typical 
amount of Hg injected into infants and toddlers via childhood immunizations has 
exceeded government safety guidelines on an individual6 and cumulative vaccine 
basis.7 The mercury in vaccines derives from thimerosal (TMS), a preservative which Drug, Healthcare and Patient Safety 2009:1 2
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is 49.6% ethylmercury (eHg).7 There may be an association 
between mercury toxicity and the onset of autism.4,8–10 This 
association is still unclear, however, since there are several 
recent reports showing no relationship between mercury 
exposure and autism.11–13
The metallothioneins (MT) are a family of small proteins 
containing 61–68 amino acids with an unusually high 
concentration of cysteine (30%). MT-1, the most functional 
and active MT in humans, has 21 cysteines. Cysteine contains 
a sulfhydryl group (SH) that has the ability to react with 
a number of metals including zinc, mercury, copper and 
cadmium.
Divalent metals such as copper, zinc, and manganese 
are toxic to cells in elemental or ionic form. These metals 
are “enveloped” or “bound” to the small linear MT, which 
supervises and regulates metal levels in blood, brain and the 
periphery and therefore plays a major role in heavy metal 
detoxiﬁ  cation of these metals.14–17
Besides detoxiﬁ  cation of heavy metals, functions of 
MT in the body include development of brain neurons, 
maturation of the GI tract, antioxidation, boosting immune 
function and delivery of zinc to cells.14,18–20 Evidence also 
suggests that autistic individuals are prone to developing 
autoimmune disorders and autism appears to be more 
common in families with a history of autoimmune 
disorders.21–24
MT dysfunction may result, then, in many of the 
issues seen with autistic children, such as the leaky gut 
syndrome, incomplete breakdown of casein/gluten protein 
by zinc-dependent enzymes, disrupted ability to combat 
yeast, reduced production of stomach acid, and impaired 
stimulation of the pancreas by secretin. It may also lead to 
inability to clear the body of heavy metals, a dysfunctional 
immune system, and ultimately to the neurological changes 
seen in ASD. It would also explain the male sex predomi-
nance (4:1) seen in autism, because MT synthesis is enhanced 
by estrogen and progesterone. In a study of 503 autism-spec-
trum patients at The Pfeiffer Treatment Center, scientists 
found abnormal levels of copper and zinc in blood indicating 
defective functioning of MT proteins.25
MT levels ﬂ  uctuate in direct response to heavy metal 
levels such as zinc.26 The ﬂ  uctuation of MT levels and/or 
the production of abnormally structured MT in autistic 
individuals may stimulate an autoimmune response.
In this study, we tested the hypothesis that levels of MT 
and anti-MT IgG might be associated with gastrointestinal 
(GI) disease, particularly inﬂ  ammation, found in many 
autistic children.
Materials and methods
ELISA to measure auto-antibodies 
to metallothionein
Purified metallothionein-1 (Sigma, St. Louis, MO), at a 
concentration of 500 ng/μl of bicarbonate buffer (pH 9.6), 
was ﬁ  xed to wells of a 96 well polystyrene microculture 
plate (Corning Glass Works Co., Corning, NY) by incubation 
overnight at 4 °C. Excess metallothionein was dumped 
from wells and all wells were blocked by washing 3× with 
300 microliters of blocking solution (Superblock, Pierce 
Chemical Co., Rockford, IL). One hundred microliters 
of primary antibody (Positive control – mouse Mab to 
metallothionein-1 diluted 1:500 with phosphate buffer solution 
[PBS]; Negative control – PBS; Experimental serum from 
autistic and nonautistic individuals diluted 1:500 with PBS) 
was added to appropriate wells and plate was incubated for 
two hours at 3 °C. All wells were washed 3× using PBS/
tween. One hundred microliters of goat anti-mouse second-
ary antibody, conjugated with alkaline phosphatase (Bio-Rad 
Laboratories, Hercules, CA), diluted 1:5000 with PBS to 
positive control; Goat anti-human (Bio-Rad) diluted 1:5000 
with PBS to all other wells, added to appropriate wells and 
incubated for 45 minutes at 37 degrees C. All wells washed 
5× with PBS/tween. One hundred microliters of substrate for 
alkaline phosphatase added to all wells and plate was incubated 
at room temperature until signiﬁ  cant color change in positive 
control. Color change measured using ELISA (enzyme-linked 
immunosorbent assay) Reader (Bio-Rad).
Indirect ELISA to quantitate the 
concentration of serum metallothionein
Human Metallothionein ELISA Kit, (USCN Life Science 
and Technology Company, Wuhan, China): Ninety-
six well microculture plate strips were coated with 
polyclonal IgG to human metallothionein. Purified 
metallothionein-1 (Sigma) at concentrations of 100 μg/ml, 
50 ng/ml, 12.5 ng/ml, 6.25 ng/ml, 3.12 ng/ml, and 1.56 ng/ml 
bicarbonate buffer (pH 9.6), and serum at a dilution of 1:100, 
were ﬁ  xed to wells of 96 well polystyrene microculture 
plate (Corning) by incubation overnight at 4 °C. Excess 
MT/serum was dumped from wells, and all wells were 
blocked by washing 3× with 300 mL of blocking solution 
(Superblock, Pierce). One hundred microliters of primary 
antibody (mouse Mab to metallothionein-1, diluted 1:500 
with PBS) was added to all wells and plate was incubated 
for 2 hours at 3 °C. All wells were washed three times using 
PBS/tween. One hundred microliters of secondary antibody, Drug, Healthcare and Patient Safety 2009:1 3
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conjugated with alkaline phosphatase (goat anti-mouse 
[Bio-Rad], diluted 1:5000 with PBS) added to all wells 
and incubated for 45 minutes at 3 °C. All wells washed ﬁ  ve 
times with PBS/tween. One hundred microliters of substrate 
for alkaline phosphatase added to all wells and plate was 
incubated at room temperature until signiﬁ  cant color change 
in positive control. Color change measured using ELISA 
Reader (Bio-Rad).
Subjects
Autistic children with GI disease
Serum from autistic individuals with GI disease was 
obtained from the Thoughtful House, Austin, Texas. These 
patients ranged in age from two to 16 years with a median 
age of 71 months. Thirty-four (85%) were male. Most 
patients were referred by their primary care physician for 
evaluation of ongoing GI symptoms, while some patients 
were parent-referred.
All patients had a diagnosis of autism, ASD, pervasive 
developmental disorder (PDD), or Asperger’s syndrome. 
The developmental diagnosis was established by either 
single or multiple members of the following specialties: 
pediatric neurologists, developmental pediatricians, pediatric 
psychiatrists, or psychologists. A clear history relating to 
the onset of developmental disorder was obtained from the 
parents of all 41 patients. Of these, the large majority (61%) 
was reported to have had a regressive onset. Regression 
was determined as a normal development until at least the 
age of 12 months followed by inexplicable loss of previ-
ously achieved developmental milestones between 12 and 
24 months and accompanied by the appearance of typical 
autistic behaviors or normal development until at least the 
age of 12 months followed by a developmental plateau in 
which milestones are not noticeably lost but the rate of 
development suffers marked deceleration, accompanied by 
the appearance of typical autistic behaviors. Nonregression 
individuals had deﬁ  nite onset of autistic behaviors prior to 
the age of 12 months.
Scoring of severity of GI disease
All the children in our study (41) had chronic GI symptoms 
and all were investigated by ileo-colonoscopy. Macroscopic 
and histological features of the upper and lower GI tract 
were scored. A point system was developed to assess 
the severity of GI disease (particularly inﬂ  ammation). 
Patients were scored according to mild (1 point), moderate 
(2 points), and marked (3 points) disease in each area 
(upper and lower GI) and for endoscopic assessment 
(macroscopic) and histological assessment of each area. 
Therefore, the maximum score for GI disease was 12 
(3 points each for upper scope, upper histology, lower 
scope, and lower histology). A point system was also 
developed for severity of lymphoid nodular hyperplasia 
(LNH). Patients were scored according to mild (1 point), 
moderate (2 points), and marked (3 points) LNH in each 
area (upper and lower GI) for a maximum of 6 points. And 
ﬁ  nally, a point system was also developed for severity of 
erythema. Patients were scored according to mild (1 point), 
moderate (2 points), and marked (3 points) erythema in 
each area (upper and lower GI) for a maximum of 6 points. 
The rationale for this scoring was to provide an objective 
and unbiased way to compare clinical and pathological 
ﬁ  ndings and immune dysfunction.
Controls
Two control groups (total n = 33) were studied, including 
17 age- (mean 68 months), gender- (80% male), and 
diagnosis- (61% regressive onset) matched autistic children 
with no GI disease and 16 age- (mean 71 months) and gender- 
(75% male) matched children without autism or GI disease. 
Serum and medical history were obtained from the Autism 
Genetic Resource Exchange [AGRE].∗
Statistics
Inferential statistics were derived from t-test and odds ratios 
with 95% conﬁ  dence intervals.
Results
We used the ELISA described above to measure serum MT 
and anti-MT IgG levels in 41 autistic children with chronic 
digestive disease and 33 age/gender-matched controls (as 
described above). All assays were performed in triplicate. 
Any variation in OD greater than 0.05 was not included 
in this data. A typical assay measuring anti-MT IgG is 
shown on Figure 1. An ELISA was performed to establish 
MT concentration/OD relationship. Normal MT serum 
concentration is approximately 80–200 mg/dL serum. 
Above 200 mg/dL (0.75 OD) was considered high (above 
normal) (Figure 2).
∗The Autism Genetic Resource Exchange (AGRE) is the ﬁ  rst collaborative 
gene bank for the study of autism spectrum disorders and one of the world’s 
largest shared resources for the study of autism and related disorders, with 
a collection of over 900 well-characterized multiplex and simplex families 
made available to the greater scientiﬁ  c community. Founded by Cure Autism 
Now (CAN) in 1997, AGRE is currently funded by the National Institute 
of Mental Health (NIMH) and Autism Speaks (AS), which merged with 
CAN in 2006.Drug, Healthcare and Patient Safety 2009:1 4
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Figure 1 A typical ELISA measuring anti-MT IgG of autistic children with GI disease (A) compared to control (C) children with no GI disease. Positive control is anti-MT IgG 
Mab and puriﬁ  ed MT. Negative control is PBS replacing anti-MT IgG.
Abbreviations: anti-MT, anti-metallothionein; ELISA, enzyme-linked immunosorbent assay; GI, gastrointestinal; IgG, immunoglobulin G; MT, metallothionein; PBS, phosphate 
buffer solution.
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Figure 2 ELISA to establish MT concentration/OD relationship. Normal MT serum concentration is approximately 80–200 mg/dL serum. Above 200 mg/dL (0.75 OD) was 
considered high (above normal).
Abbreviations: ELISA, enzyme-linked immunosorbent assay; MT, metallothionein; OD, oxidation ditch.Drug, Healthcare and Patient Safety 2009:1 5
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Ten of 41 autistic children with chronic digestive disease 
had high serum concentration of metallothionein compared 
to only one of the 33 controls (Figure 3) (p  0.01).
Thirteen of the 41 autistic children with chronic digestive 
disease had anti-MT IgG compared to only four of 33 controls 
(Figure 4) (p  0.01).
Nine of 10 of autistic children with GI disease with high 
MT levels had a regressive onset (compared to the expected 
25 of 41, or 61%, in this group) (p  0.05), whereas, only 
nine of 13 of the autistic children with GI disease and anti-MT 
IgG had a regressive onset (70%) which was not signiﬁ  cantly 
higher than expected (Table 1).
We didn’t ﬁ  nd any correlation between severity of GI 
disease and MT concentration. Only four of 10 autistic 
children with GI disease with high metallothionein levels 
also had severe GI disease (Table 1) (P  0.1). However, 
although only six of 14 with high anti-MT IgG had severe 
GI disease, four of ﬁ  ve of those autistic children with severe 
GI erythema, and four of six with severe LNH had these 
auto-antibodies (Table 1) (p  0.05).
Typical ELISA Anti-MT IgG
Mean OD +/– SD
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Figure 3 Ten of 41 autistic children with chronic digestive disease had high serum concentration of metallothionein compared to only one of the 33 controls (Figure 1) 
(p  0.01).
ELISA to establish MT Concentration/OD Relationship
negative 100 200 300 400
MT Concentration mg/dL
1
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0
O
D
 
+
/
−
 
S
D
Figure 4 Thirteen of the 41 autistic children with chronic digestive disease had high levels (OD  0.63 based on greater than mean ± SD of normal controls) of anti-MT 
IgG compared to only 4 of 33 controls.
Abbreviations: anti-MT, anti-metallothionein; IgG, immunoglobulin G; MT, metallothionein; OD, oxidation ditch.Drug, Healthcare and Patient Safety 2009:1 6
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Table 1 Nine of 10 of autistic children with GI disease with high MT levels had a regressive onset (compared to the expected 25 of 
41, or 61%, in this group) (p  0.05), whereas only nine of 13 of the autistic children with GI disease and anti-MT IgG had a regressive 
onset (70%) which was not signiﬁ  cantly higher than the expected. Only four of 10 autistic children with GI disease with high MT levels 
also had severe GI disease (P  0.1). However, although only six of 14 with high anti-MT IgG had severe GI disease, four of ﬁ  ve of those 
autistic children with severe GI erythema, and four of six with severe LNH had these autoantibodies.
LNH Eryth Total GI MT Mean OD Anti-MT Mean OD
A3 69 0.686 0.78
R-PDD 1 0 3 0.561 0.823
RA 1 0 3 0.612 1.012
RA 2 2 6 0.907 0.508
RA 43 8 0.601 0.63
RA 2 0 8 0.563 0.356
R-UD 4 2 8 0.675 0.43
RA 3 1 7 0.75 0.445
A 3 1 6 0.688 0.466
RA 1 0 7 0.678 0.459
PDD/NOS 2 2 6 0.622 2.225
A 1 2 6 0.571 0.433
A3 51 0 0.655 0.461
RA 0 2 5 0.521 0.394
A 2 1 5 0.708 0.488
RA 3 1 NA 0.729 0.401
A NA NA NA 0.72 0.528
R-PDD 5 0 NA 0.742 0.634
A 4 4 11 0.933 0.655
R-PDD 3 1 8 0.643 2.055
RA 3 2 5 0.67 0.521
RA 3 0 7 0.641 0.87
A3 2 8 0.654 0.596
RA 2 0 4 0.826 0.515
RA 3 0 4 0.799 0.457
R-ASP 2 1 6 0.762 0.345
A3 4 6 0.678 0.645
PDD 2 1 4 0.62 0.596
R-PDD/NOS 2 1 4 0.609 0.548
RA 3 0 6 0.615 1.052
A-dev. plateau 2 0 4 0.656 0.417
A NA NA NA 0.833 0.462
RA 3 2 6 0.771 0.416
A 0 0 NA 0.71 0.368
RA 3 0 5 0.991 1.227
RA 2 2 7 0.684 0.597
A NA NA NA 0.662 0.633
RA 2 0 3 0.636 0.423
A 4 0 7 0.718 0.499
RA 3 2 7 0.761 0.406
RA 6 0 10 0.769 0.646
Notes: Diagnosis: A, autistic early onset; RA, regressive onset; ASP, Asperger’s syndrome patients; PDD, pervasive developmental disorder.
Abbreviations: anti-MT, anti-metallothionein; ELISA, enzyme-linked immunosorbent assay; GI, gastrointestinal; IgG, immunoglobulin G; LNH, lymphoid nodular hyperplasia; 
MT, metallothionein.Drug, Healthcare and Patient Safety 2009:1 7
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Discussion
Autoimmune reactions after exposure to heavy metals such 
as mercury have been causally implicated in autism. As 
MT is the primary metal-detoxifying protein in the body, 
we conducted a study of serum MT and antibodies to MT 
in 41 autistic children with severe GI disease, and 33 age/
gender-matched controls.
Metallothioneins (MT), a family of small proteins 
containing 61–68 amino acids with an unusually high 
concentration of cysteine, function as intracellular distribu-
tors and mediators of heavy metals, including copper and 
zinc, and heavy metal detoxiﬁ  cation.
Data indicates that copper to zinc ratio is abnormally 
high in individuals with autism.25 This might be explained 
by an altered function due to an altered conformation of the 
protein.
Measurements of MT levels, as well as zinc, have been 
used to demonstrate zinc deﬁ  ciency. MT increases rapidly 
after zinc supplementation and decreases if the diet is 
deﬁ  cient in zinc.26
Studies indicate that many children with autism 
have an immune abnormality of some type, including 
myeloperoxidase deﬁ  ciency, severe combined immunode-
ﬁ  ciency, and IgA deﬁ  ciencies. Twenty percent of autistics 
have IgG subclass deﬁ  ciencies, and deﬁ  ciencies in comple-
ment C4b. Concentrations of IL-12 and interferon gamma are 
much higher in autistic children than in normal children.27–31 
Autistic individuals are also susceptible to autoimmune 
disorders.32,33
It has previously been reported that anti-MT antibody is 
present in the circulation of healthy persons, including both 
normal and autistic children.34,35
Singh and Hanson reported in 200636 that serum levels 
of MT did not signiﬁ  cantly differ between normal and 
autistic children. Furthermore, autistic children harbored 
normal levels of anti-MT, without any signiﬁ  cant difference 
between normal and autistic children. They suggested that, 
because autistic children have a normal proﬁ  le of MT and 
anti-MT, the mercury-induced autoimmunity to MT may not 
be implicated in the pathogenesis of autism.
In a previous study,37 we found that a signiﬁ  cant number 
of autistic family members (parents and children) had high 
levels of anti-MT and serum MT, but the levels of MT and 
anti-MT did not correlate with autism (parents and nonautistic 
children were just as likely to have high levels). In that study, 
however, the only demographic group, which seemed to have 
higher levels of anti-MT IgG than the controls (although not 
signiﬁ  cant), was the group with GI disease.
In this study, we looked more carefully at autistic children 
with GI disease and found that they had a signiﬁ  cantly higher 
concentration of serum MT and anti-MT antibodies when 
compared to age/gender-matched controls of autistic chil-
dren without GI disease and nonautistic children without GI 
disease. This suggests an association between the GI disease 
seen in many autistic children and serum levels of MT and 
anti-MT IgG. It is possible that the presence of anti-MT 
IgG in this subgroup could be associated with the fact that 
autistic children are more susceptible to immune dysfunction, 
including autoimmune disease. However, it is still unclear 
whether high levels of MT or the presence of anti-MT IgG 
is associated with a cause of GI disease or the result of other 
immune dysfunction found in autistic children.
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